Legal Fight Could Delay a Proposed $7B Settlement for Lawsuits in Roundup Cancer Claims

Why It Matters

The jurisdiction fight could postpone compensation for tens of thousands of cancer victims and reshape how mass tort settlements are handled in the United States.

Key Takeaways

• Federal court petition could push settlement beyond July deadline
• Opt‑out threshold may trigger cancellation of the $7.25B deal
• Supreme Court decision on glyphosate carcinogenicity looms
• Payouts range from $10K to $165K based on exposure and age

Pulse Analysis

The Roundup litigation has become one of the largest product‑liability battles in recent memory, with Bayer offering a $7.25 billion fund to resolve claims that its glyphosate‑based weedkiller caused non‑Hodgkin lymphoma. The settlement, filed in a St. Louis circuit court, would distribute payments over 21 years, scaling from roughly $10,000 for older, less‑exposed claimants to $165,000 for younger, heavily exposed workers. By consolidating thousands of state‑court suits, Bayer hopes to cap its exposure and restore investor confidence after a series of adverse verdicts.

A new procedural hurdle emerged when plaintiff attorney Ashley Keller submitted paperwork to shift the case to federal court, arguing that the state‑level process rushed the settlement and stripped claimants of rights. If a federal judge takes jurisdiction, the existing June 4 opt‑out deadline and the July 9 hearing could be postponed, potentially delaying any payouts. Bayer and its pro‑settlement counsel contend the move is a delay tactic, while opponents warn that a federal forum may favor broader discovery and a more rigorous review of the settlement’s fairness.

The timing is critical because the U.S. Supreme Court is poised to decide a separate case challenging the EPA’s stance that glyphosate is unlikely to cause cancer. A ruling that reclassifies the chemical as a carcinogen could revive thousands of state lawsuits and pressure Bayer to renegotiate the fund. For claimants, the jurisdiction dispute adds uncertainty to expected compensation, while for investors, the outcome will influence Bayer’s financial outlook and its ability to move past the Roundup controversy.